In vitro studies showed that, in contrast to gefitinib, cetuximab inhibited proliferation in EGFR wild-type NSCLC cell lines only but was not effective against cell lines carrying activating EGFR mutations and could not inhibit the phosphorylation of mutant EGFR [216]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.